BioCentury
DATA GRAPHICS | Data Byte

Korean biopharma leads top IPOs of 2021

Each of this year’s top 25 IPOs raised over $250M; it’s the second straight win for a Korean company

December 16, 2021 12:27 AM UTC

Like last year, this year’s biggest IPO by a therapeutics developer was raised on the Korea Stock Exchange, but 2021’s offering was more than 60% larger.

In its March listing, SK Bioscience Co. Ltd. (KSE:302440) brought in $1.3 billion to support the company’s ambition of building a global vaccines company. The offering came nine months after its SK Group affiliate SK Biopharmaceuticals Co. Ltd. (KSE:326030) raised nearly $800 million in an IPO, marking 2020’s largest biopharma IPO, according to BioCentury’s BCIQ database...